pixlbio Wild-Type iPSC-derived hepatocyte models address population diversity

Population differences in drug efficacy and toxicity are a wellrecognized challenge in drug discovery. These differences arise from a complex interplay of genetic, environmental, physiological, and behavioral factors that influence drug activity, metabolism, and clearance. Current models, however, fail to capture this variability: animal models assess efficacy and safety only within a single species, while in vitro liver models (e.g., primary human hepatocytes or hepatocellular carcinoma cell lines) are either limited in availability or derived from a single donor source. iPSCderived cell models representing individuals of diverse ages, genders, and ethnicities can overcome these limitations, providing a robust platform to study how population diversity influences drug response early in development. At pixlbio, we hold a license to a diverse panel of wild-type donors, enabling the production of best-in-class iPSC-derived hepatocytes that address population heterogeneity.